obj chart, page-19

Same was said for Thermalife of the sister company which has since then disappeared into endless suspension. Many people praised Thermalife as the answer to their pain management problems, it did very little though to help the ever declining share price.

We do have the backing of P&G but roll out of product so far is far less impressive than anticipated by many in here, therefore revenue is a big question mark and not shared with the public.

When posters take refuge in praising the product coming out of the Perth it does ring familiar bells.



As one poster here said, this bunch of directors who were involved in both companies, has the hard earned reputation of looking after themselves well.

A CR would have to be decided on quickly before share price falls any further as just fell below important support levels yet again. A second break through support could be followed by accelerated selling pressure as the bargain buyers from the first break through would very likely be exhausted in buying power.

The recent update clearly hinted towards product developments for their own product, as pointed out by Jarrody.
It was always management's goal to push ahead with Bodyguard as early as possible.